"Kevin Riggs, an instructor in medicine at Johns Hopkins University who co-authored an article about generic insulin earlier this year, doesn't think that Open

"Kevin Riggs, an instructor in medicine at Johns Hopkins University who co-authored an article about generic insulin earlier this year, doesn't think that Open Insulin will be enough to bring a generic insulin drug to the market: “I don't think the major hurdle is that the companies don't know how to make insulin, because that part is reasonably straightforward,” he says. “The real hurdles are getting the drug approved by the FDA (and since insulin is a biologic drug, it requires a lot more original data than an application for a small-molecule generic would), and then upfront manufacturing costs (because making a biologic drug is different, so it requires different equipment).” "